Outcome of Board Meeting Held On May 14, 2025 is attached
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.2 pts less than Nifty Microcap 250 and 6.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board approved audited financial results for Q4 and FY ending March 31, 2025, with an unmodified auditor opinion from Naresh & Co. FY25 revenue from operations came in at Rs 7,510 lakhs, marginally down from Rs 7,556 lakhs in FY24. Net profit after tax fell sharply to Rs 314 lakhs from Rs 565 lakhs in FY24, while Q4 standalone revenue rose about 19% YoY to Rs 2,066 lakhs. The board recommended a final dividend of 35% (Rs 3.50 per share) subject to shareholder approval. Mr. Sanjay Patel was appointed as Additional Non-Executive Independent Director and Chairman, Mr. Rajendra R Shah's term as Managing Director was renewed for three years from April 1, 2026, and Mr. Bharat Mehta retired on completing his second term as Independent Director. The 44th AGM will be held on August 13, 2025 via video conferencing.
Stable top-line but a steep ~44% drop in annual net profit may weigh on near-term sentiment, though the continued dividend payout signals cash comfort. Board continuity is largely preserved, with leadership reinforcement at the chairman level.